BC
BCHMF.US Bachem Holding AG
- Market cap
- USD 6.82B
- P/E
- 36.5x
- P/B
- 3.91x
- ROE
- 13.9%
- Dividend yield
- 1.27%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BCHMF.US undervalued?
Graham numberBCHMF.US trades 152.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bachem Holding AG fundamental analysis
No fundamental analysis for Bachem Holding AG yet.
Bachem Holding AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical…
Full company profileBachem Holding AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bachem Holding AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 236M | 262M | 283M | 314M | 402M | 503M | 532M | 577M | 605M | 695M | 1.30B |
| Gross Profit | 77.2M | 82.7M | 83.2M | 92.5M | 129M | 167M | 171M | 177M | 183M | 200M | 325M |
| Operating Income | 45.1M | 50.6M | 54.8M | 62.4M | 96.7M | 129M | 127M | 129M | 133M | 150M | 213M |
| EBITDA | 65.8M | 69.6M | 78.2M | 85.7M | 117M | 160M | 145M | 162M | 179M | 190M | 327M |
| Net Income | 41.2M | 41.8M | 46.6M | 54.2M | 78.1M | 115M | 101M | 112M | 120M | 149M | 200M |
| EPS | 0.61 | 0.62 | 0.69 | 0.78 | 1.12 | 1.62 | 1.37 | 1.50 | 1.60 | 1.99 | 2.67 |
| Balance Sheet | |||||||||||
| Total Assets | 497M | 545M | 615M | 647M | 711M | 1.30B | 1.38B | 1.68B | 1.92B | 2.11B | 2.33B |
| Total Liabilities | 131M | 170M | 230M | 199M | 235M | 177M | 214M | 362M | 532M | 651M | 890M |
| Shareholders' Equity | 365M | 374M | 384M | 448M | 476M | 1.12B | 1.17B | 1.32B | 1.39B | 1.46B | 1.44B |
| Cash & Short-term Investments | 19.2M | 17.3M | 22.3M | 21.4M | 23.5M | 442M | 268M | 299M | 95.2M | 31.0M | 51.3M |
| Total Debt | 55.4M | 94.9M | 150M | 60.2M | 108M | 20.9M | 691K | 401K | 290K | 57.4M | 207M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 40.4M | 35.7M | 25.8M | 64.3M | 115M | 97.6M | 92.6M | 250M | 146M | 271M | 415M |
| Capital Expenditure | 51.3M | 50.4M | 38.0M | 30.6M | 69.1M | 117M | 142M | 268M | 285M | 320M | 638M |
| Free Cash Flow | -10.9M | -14.7M | -12.2M | 33.7M | 45.9M | -19.3M | -49.7M | -18.5M | -138M | -48.2M | -223M |
| Ratios | |||||||||||
| ROE | 11.3% | 11.2% | 12.1% | 12.1% | 16.4% | 10.2% | 8.6% | 8.5% | 8.6% | 10.2% | 13.9% |
| ROA | 8.3% | 7.7% | 7.6% | 8.4% | 11.0% | 8.8% | 7.3% | 6.6% | 6.3% | 7.1% | 8.6% |
| Net Profit Margin | 17.4% | 16.0% | 16.5% | 17.3% | 19.4% | 22.8% | 18.9% | 19.4% | 19.9% | 21.4% | 15.4% |
| Debt to Equity | 0.15x | 0.25x | 0.39x | 0.13x | 0.23x | 0.02x | 0.00x | 0.00x | 0.00x | 0.04x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bachem Holding AG dividends
- Dividend yield
- 1.27%
- Forward dividend
- 1.15 USD
- Payout ratio
- 20.7%
- Ex-dividend date
- May 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CHF 30.7M | 0.41 | 20.7% |
| 2024 | CHF 60.0M | 0.80 | 49.9% |
| 2023 | CHF 56.2M | 0.75 | 50.3% |
| 2022 | CHF 51.6M | 0.70 | 51.3% |
| 2021 | USD 20.5M | 0.29 | 17.9% |
| 2020 | USD 42.0M | 0.60 | 53.8% |
| 2019 | USD 27.4M | 0.40 | 50.5% |
| 2018 | USD 27.4M | 0.40 | 58.7% |
| 2017 | USD 23.9M | 0.35 | 57.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on May 5, 2022.
Who owns Bachem Holding AG
- Insiders 0.25%
- Institutions 82.70%
- Public & others 17.05%
- Shares outstanding 74.9M
- Free float 31.2M
Bachem Holding AG company profile
- Company name
- Bachem Holding AG
- Ticker
- BCHMF.US
- ISIN
- CH0012530207
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Chemicals
- Employees
- 2,725
- Fiscal year end
- December
- Address
- Hauptstrasse 144, Bubendorf, Switzerland, 4416
- Phone
- 41 58 595 2021
- Website
- bachem.com
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Bachem Holding AG management
10- Dr. Anne-Kathrin Stoller Ph.D.Chief Executive Officer · born 1974
- Mr. Alain SchaffterChief Financial Officer · born 1977
- Mr. Hans van HeesChief Operations Officer · born 1969
- Mr. Michael SuterVice President of Global Accounting
- Dr. Gunther LoidlChief Technology Officer · born 1970
- Mr. Achim PluckebaumChief Information Officer
- Ms. Barbora BlahaHead of Investor Relations
- Dr. Daniel GrotzkyHead of Group Communications
- Viviane MindenChief Human Resources Officer
- Mr. Boris CorpatauxChief Commercial Officer, VP & Head Global Strategic Alliances